Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.37 |
| ▸ | CAMKK1 | Q8N5S9 | 2/20 | 0.35 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.35 |
| ▸ | KDM5A | P29375 | 3/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.32 |
| ▸ | KDM4A | O75164 | 2/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL982755 | 0.92 | KDM4C (0.39) | KDM4CCAMKK1CAMKK2KDM5AKMO | |
| SCHEMBL984962 | 0.90 | JAK3 (0.40) | — | |
| SCHEMBL983554 | 0.88 | KDM4C (0.39) | KDM4CCAMKK1CAMKK2KDM5AKMO | |
| SCHEMBL983558 | 0.87 | PDE4B (0.36) | KDM4CCAMKK1CAMKK2KDM5AKMO | |
| SCHEMBL985069 | 0.86 | KDM4C (0.38) | KDM4CCAMKK1CAMKK2KDM5AKMO | |
| SCHEMBL985692 | 0.82 | KDM5A (0.44) | KDM4CKDM5AKMOHTR2AHTR2C | |
| SCHEMBL985123 | 0.82 | JAK3 (0.41) | — | |
| SCHEMBL986385 | 0.82 | BRD4 (0.43) | KDM4CKDM5AKMOHTR2AHTR2C | |
| SCHEMBL982011 | 0.81 | SCN9A (0.40) | SCN9A | |
| Tert-Butyl Formate SCHEMBL27803004 | 0.81 | PTK2 (0.34) | WDR5SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101959890-B | Pyrrolopyrimidine carboxamides | NYCOMED GMBH | 2013-10-30 | — | — | CN | disclosed |
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| CN-101959890-A | Pyrrolopyrimidine carboxamides | NYCOMED GMBH | 2011-01-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | KDM4C 599/4885CAMKK1 1875/4885CAMKK2 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.